GABRD: IHC Expression in Cancer and Radioligand Target Profile
GABRD, gamma-aminobutyric acid type A receptor subunit delta, is a cell-surface protein (membrane receptor). In Human Protein Atlas immunohistochemistry, GABRD staining is highest in neuroendocrine tumors (100% of samples positive), thyroid cancer (33% of samples positive) and prostate cancer (55% of samples positive). Evidence on whether GABRD internalizes is mixed. Clinical status: FDA-approved drug (any modality).
Is GABRD the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.
Analyze GABRD freeIs GABRD a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ⚠️ Tumor expression: Medium IHC staining in neuroendocrine tumors, 100% of samples positive.
- ⚠️ Internalization: Mixed evidence.
- ✅ Clinical precedent: FDA-approved drug (any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
GABRD IHC staining by cancer type
Protein expression of GABRD across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Neuroendocrine Tumors | 0.42 | Medium | 100% |
| Thyroid Cancer | 0.22 | Medium | 33% |
| Prostate Cancer | 0.21 | Medium | 55% |
| Colorectal Cancer | 0.17 | Low | 50% |
| Breast Cancer | 0.15 | Low | 36% |
| Endometrial Cancer | 0.15 | Low | 36% |
| Liver Cancer | 0.11 | Low | 33% |
| Lung Cancer | 0.09 | Low | 18% |
| Gastric Cancer | 0.03 | Low | 10% |
| Testicular Cancer | 0.03 | Low | 10% |
| Skin Cancer | 0.03 | Low | 9% |
| Kidney Cancer | 0.03 | Low | 9% |
| Ovarian Cancer | 0.03 | Low | 8% |
Not detected by IHC in: head and neck cancer, lymphoma, melanoma, bladder cancer, cervical cancer, pancreatic cancer, glioma.
Is GABRD internalized?
Uncertain. Insufficient literature found.
GABRD clinical trials
FDA-approved drug (any modality). Nuclens hasn't indexed trials for GABRD yet. Search ClinicalTrials.gov for GABRD trials.
GABRD normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See GABRD in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
GABRD gene essentiality (DepMap)
CRISPR knockout effect across 1244 cancer cell lines: -0.06 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related neuroendocrine tumors radioligand targets
HER3 (ERBB3) · c-MET (MET) · SSTR2 · STEAP2 · EPCAM · ITGB6 · KIT · FAP
See all radioligand therapy targets in neuroendocrine tumors.
See how GABRD ranks against 15,000 targets for your indication.
Analyze GABRD freeData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.